Acadia Pharma raised the price of its only drug twice but quarterly sales still disappoint

first_img Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. @adamfeuerstein Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Acadia Pharmaceuticals (ACAD) either didn’t receive — or is ignoring — the Big Pharma etiquette memo about easing back on egregious drug-price hikes.During the fourth quarter, the San Diego-based company acknowledged Tuesday night, it took two price increases for Nuplazid, a pill used to quell hallucinations and delusions often experienced by people with advanced Parkinson’s disease. About the Author Reprints Log In | Learn More What’s included? What is it? Acadia Pharma raised the price of its only drug twice but quarterly sales still disappoint [email protected] Tags biotechdrug pricesSTAT+ By Adam Feuerstein Feb. 28, 2018 Reprints Senior Writer, Biotech Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast. Adam’s Take Adam Feuersteinlast_img read more